SCHEMBL325804

SCHEMBL325804

CCC(CO)OC(CC)CO

nearest known ligand 0.40

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.40
LMNA P02545 3/20 0.33
TDP1 Q9NUW8 2/20 0.33
CNR1 P21554 1/20 0.33
ADRA1A P35348 1/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 2/20 0.32
ABCC3 O15438 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15628682 0.97 TSHR (0.38) TSHRLMNATDP1CNR1ADRA1A
SCHEMBL13877207 0.97 TSHR (0.38) TSHRLMNATDP1CNR1ADRA1A
SCHEMBL8529610 0.90 TSHR (0.38) TSHRLMNATDP1CNR1ADRA1A
SCHEMBL10486462 0.87 TSHR (0.32) TSHR
SCHEMBL24094055 0.85
SCHEMBL224194 0.85
SCHEMBL10100320 0.85
SCHEMBL15810584 0.83 TSHR (0.60) TSHRLMNATDP1
SCHEMBL10100324 0.83 TSHR (0.33) TSHRTDP1
SCHEMBL223185 0.83 TSHR (0.33) TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108949104-B Anti-seepage composition and using method 王鹏 2021-06-25 CN disclosed
US-10759966-B1 Optical laminate and flexible display apparatus comprising the same LG CHEM, LTD. (KR) 2020-09-01 US disclosed
US-20180030207-A1 LINEAR CYCLODEXTRIN COPOLYMERS CALIFORNIA INSTITUTE OF TECHNOLOGY 2018-02-01 US disclosed
US-20170049903-A1 COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES CALIFORNIA INSTITUTE OF TECHNOLOGY 2017-02-23 US disclosed
WO-2015130890-A9 SYNTHETIC SALT COMPLEXES FOR IMPROVEMENT OF PLANT GROWTH AND YIELD E. I. DU PONT DE NEMOURS AND COMPANY (US) 2016-09-29 WO disclosed
WO-2015134256-A1 COMBINATORIAL LIBRARIES E. I. DU PONT DE NEMOURS AND COMPANY (US) 2015-09-11 WO disclosed
WO-2015130893-A1 SYNTHETIC OLIGOGLUCOSAMINES FOR IMPROVEMENT OF PLANT GROWTH AND YIELD E. I. DU PONT DE NEMOURS AND COMPANY (US) 2015-09-03 WO disclosed
WO-2015130890-A1 SYNTHETIC SALT COMPLEXES FOR IMPROVEMENT OF PLANT GROWTH AND YIELD E. I. DU PONT DE NEMOURS AND COMPANY (US) 2015-09-03 WO disclosed
US-20150203634-A1 LINEAR CYCLODEXTRIN COPOLYMERS CALIFORNIA INSTITUTE OF TECHNOLOGY 2015-07-23 US disclosed
US-20150050233-A1 COMPOSITIONS CONTAINING INCLUSION COMPLEXES CALANDO PHARMACEUTICALS, INC. (US) 2015-02-19 US disclosed
US-7018609-B2 Compositions containing inclusion complexes CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2006-03-28 US disclosed
US-6884789-B2 Linear cyclodextrin copolymers CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2005-04-26 US disclosed
EP-1351710-A2 COMPOSITIONS CONTAINING INCLUSION COMPLEXES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2003-10-15 EP disclosed
US-20030017972-A1 Complexing agents for compositions containing inclusion complexes CALIFORNIA INSTITUTE OF TECHNOLOGY AND INSERT THERAPEUTICS, INC 2003-01-23 US disclosed
US-6509323-B1 Cyclodextrin copolymers may be used as a delivery vehicle of various therapeutic agents CALIFORNIA INSTITUTE OF TECHNOLOGY 2003-01-21 US disclosed
US-20030008818-A1 Compositions containing inclusion complexes CALIFORNIA INSTITUTE OF TECHNOLOGY AND INSERT THERAPEUTICS, INC 2003-01-09 US disclosed
US-20020151523-A1 Linear cyclodextrin copolymers CALIFORNIA INSTITUTE OF TECHNOLOGY 2002-10-17 US disclosed
WO-2002049676-A2 COMPOSITIONS CONTAINING INCLUSION COMPLEXES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2002-06-27 WO disclosed
EP-1133318-A1 SUPRAMOLECULAR COMPLEXES CONTAINING THERAPEUTIC AGENTS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2001-09-19 EP disclosed
WO-2000033885-A1 SUPRAMOLECULAR COMPLEXES CONTAINING THERAPEUTIC AGENTS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2000-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008818-A1 Compositions containing inclusion complexes EXOSC5, EXOSC9, INTS6 TSHR 4512/4885LMNA 1461/4885TDP1 1502/4885
US-20180030207-A1 LINEAR CYCLODEXTRIN COPOLYMERS DDOST, SI, PDIA6 TSHR 4451/4885LMNA 3425/4885TDP1 2773/4885
US-20030017972-A1 Complexing agents for compositions containing inclusion complexes INTS6, EXOSC5, PCBP1 TSHR 4563/4885LMNA 1644/4885TDP1 1686/4885
US-20150050233-A1 COMPOSITIONS CONTAINING INCLUSION COMPLEXES EXOSC5, EXOSC9, INTS6 TSHR 4519/4885LMNA 1441/4885TDP1 1685/4885
US-20020151523-A1 Linear cyclodextrin copolymers DDOST, SI, PDIA6 TSHR 4451/4885LMNA 3425/4885TDP1 2773/4885
US-20170049903-A1 COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES INTS6, EXOSC5, PCBP1 TSHR 4564/4885LMNA 1557/4885TDP1 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.